Chemotherapy for Metastatic Melanoma

Chemotherapy for Advanced or Metastatic Melanoma

Metastatic melanoma occurs when cancer spreads beyond its original location to distant tissues or organs, such as the lungs, liver, bones, or brain. Stage IV melanoma indicates distant metastasis, while some stage III melanomas cannot be removed completely through surgery.

For many patients with advanced melanoma, immune checkpoint inhibitors are preferred systemic treatments. Patients whose tumors have certain molecular alterations, including eligible BRAF mutations, may also benefit from targeted therapy. The sequence of treatment depends on disease characteristics, previous therapies, and the need for disease control.

Chemotherapy may be considered when these options are no longer effective, cannot be tolerated, or are otherwise unsuitable. In some circumstances, its purpose is to reduce tumor burden, slow disease progression, or help relieve cancer-related symptoms.

Chemotherapy Drugs Used for Melanoma

Several conventional chemotherapy medications have been used to treat metastatic melanoma. Their usefulness depends on the clinical situation, and none should be assumed to be the preferred initial treatment for all patients.

Medications that may be considered include:

• Dacarbazine (DTIC): An intravenous chemotherapy drug with a long history of use in metastatic melanoma.
• Temozolomide: An oral chemotherapy medication that has been used for advanced melanoma, although it has not demonstrated superior survival outcomes compared with dacarbazine.
• Taxane-Based Chemotherapy: Medications such as paclitaxel or nab-paclitaxel may be considered in selected circumstances.
• Platinum-Based Regimens: Drugs such as carboplatin may be combined with other chemotherapy agents for particular patients.

The choice of medication takes into account previous treatment, anticipated benefit, potential side effects, performance status, and the patient’s goals. Some patients may be better served by another systemic therapy, a clinical trial, or supportive treatment focused on symptom relief.

Is Chemotherapy Used After Melanoma Surgery?

For most patients with melanoma that has been completely removed, conventional chemotherapy is not routinely recommended to prevent recurrence. When additional postoperative treatment is indicated, modern approaches more commonly involve immunotherapy or, for eligible tumors with specific BRAF mutations, targeted therapy.

Surgery remains an important treatment for localized melanoma, commonly involving Wide Local Excision. The need for additional treatment depends on the stage, pathological findings, recurrence risk, and other clinical factors.

Some patients with advanced melanoma may also undergo surgery or radiation to treat particular areas of disease. These local treatments serve different purposes from systemic chemotherapy and are selected according to the patient’s overall disease pattern.

Electrochemotherapy and Other Specialized Approaches

Electrochemotherapy combines selected chemotherapy drugs with short electrical pulses that temporarily increase the ability of medication to enter tumor cells. It has been used in specialized settings for certain skin or subcutaneous tumor deposits, including cutaneous melanoma metastases.

Electrochemotherapy is not equivalent to conventional systemic chemotherapy and is not a routine first-line treatment for metastatic melanoma. Its availability and suitability depend on the clinical setting, tumor characteristics, and treatment expertise.

Preparing for Chemotherapy

Before treatment begins, clinicians review the patient’s medical history, previous cancer therapies, medications, and any conditions that could affect treatment safety. Blood tests are commonly performed to evaluate blood cell counts and organ function, and additional assessment may be needed depending on the prescribed drug.

Patients should discuss prescription medications, over-the-counter products, supplements, and any previous reactions to cancer treatment with their care team. The team may also recommend medications to reduce nausea or other anticipated side effects.

Common Side Effects of Chemotherapy

Side effects vary according to the medication, dose, schedule, and individual patient. Chemotherapy can affect healthy rapidly dividing cells as well as cancer cells, although not every patient experiences every side effect.

Possible side effects include:

• Fatigue: Reduced energy or increased tiredness during treatment.
• Nausea and Vomiting: Digestive symptoms that can often be reduced with supportive medications.
• Lowered Blood Cell Counts: Reduced white blood cells, red blood cells, or platelets, potentially increasing the risk of infection, anemia, or bleeding.
• Loss of Appetite: Changes in appetite, taste, or the ability to maintain adequate nutrition.
• Mouth Sores: Irritation or inflammation of tissues inside the mouth.
• Hair Thinning or Loss: Possible with certain chemotherapy regimens, although the extent varies.
• Changes in Bowel Function: Diarrhea or constipation associated with particular medications or supportive treatments.
• Other Drug-Specific Effects: Some regimens may cause numbness, tingling, allergic reactions, or effects on organ function.

Patients receiving chemotherapy should promptly report fever, chills, unusual bleeding, shortness of breath, persistent vomiting, or other concerning symptoms. Fever during periods of low white blood cell counts can signal a serious infection and requires urgent medical assessment.

Monitoring Treatment Response

During chemotherapy, the oncology team monitors symptoms, laboratory findings, medication tolerance, and the cancer’s response. Imaging studies may be performed at appropriate intervals to determine whether tumors are shrinking, remaining stable, or progressing.

If treatment is not providing adequate benefit or side effects become difficult to manage, clinicians may adjust the regimen, consider another treatment, or reassess the goals of care. Decisions take into account both disease control and the patient’s quality of life.

Supportive Care During Treatment

Supportive care is an important component of cancer treatment and may include medications for nausea, evaluation of treatment-related fatigue, nutritional support, pain management, or other services. These interventions can help patients manage symptoms and maintain daily function.

Supportive and palliative care may be provided alongside cancer-directed treatment and do not necessarily mean treatment is ending. Patients and families can discuss available resources with their oncology team according to their needs.

Individualized Treatment Recommendations

Medical oncologists may work with surgical oncologists, radiation oncologists, pathologists, radiologists, and other specialists to evaluate treatment options. For complex cases, multidisciplinary discussion can help clarify whether additional systemic therapy, treatment of specific metastatic sites, or other approaches are appropriate.

Important considerations include whether the melanoma has a targetable molecular alteration, which systemic therapies have already been used, how the disease has responded, and what side effects or medical conditions may affect the next treatment choice.

Clinical Trials and Additional Treatment Options

Clinical trials continue to evaluate new melanoma treatments and ways to improve care when established therapies are insufficient. Depending on eligibility and availability, patients with advanced melanoma may be candidates for trials involving immunotherapy, targeted treatment, cellular therapies, or other investigational approaches.

Patients who have previously received immunotherapy or targeted therapy may also have additional established treatment options. A review of prior treatment and current disease findings can help determine whether chemotherapy, another approved treatment, or a clinical trial is appropriate.

Questions to Discuss With Your Oncology Team

Understanding why a specific treatment is recommended can help patients weigh its potential benefits and risks. Questions may include whether other therapies are appropriate, what chemotherapy is expected to accomplish, how response will be measured, and which side effects require immediate attention.

Patients may also ask about expected treatment duration, quality-of-life considerations, available supportive services, and whether a second opinion or clinical trial could provide additional options.